New drug duo aims to wipe out lingering cancer cells
NCT ID NCT07191717
Summary
This study is testing whether two oral drugs, imlunestrant and abemaciclib, can clear tiny amounts of leftover cancer DNA from the blood in people with early-stage, hormone-sensitive breast cancer. The goal is to see if this treatment can prevent the cancer from coming back. About 42 participants who have already had standard treatment but still show signs of cancer DNA will take the drugs for up to a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.